Orchestra Biomed Holdings, INC Form 4 insider transactions

Orchestra BioMed Holdings CEO David P. Hochman purchased 20,000 shares of common stock at $2.75 per share in a public offering.

Orchestra BioMed Holdings, Inc. Director Eric S. Fain sold 2,683 shares of common stock for $3.05 per share to cover tax obligations related to the vesting of restricted stock units.

Orchestra BioMed Holdings, Inc. Director Jason Aryeh was granted 12,422 restricted stock units and 36,797 stock options as part of his compensation, aligning his interests with shareholders.

Orchestra BioMed Holdings, Inc. Director Chris Cleary received an award of 12,422 restricted stock units and 36,797 stock options, aligning his interests with shareholders.

Orchestra BioMed Holdings, Inc. Director John Mack was granted 12,422 Restricted Stock Units and 36,797 stock options on June 24, 2025, as part of his compensation.

Orchestra BioMed Holdings, Inc. Director Pamela Ann Connealy was granted 12,422 restricted stock units and 36,797 stock options as part of her compensation.

Orchestra BioMed Holdings, Inc. Director Eric S. Fain has been granted 12,422 restricted stock units and 36,797 stock options, aligning his interests with the company's long-term performance.

Orchestra BioMed Holdings, Inc. Director David Pacitti received an award of 12,422 restricted stock units and 36,797 stock options on June 24, 2025, as part of his compensation.

Orchestra BioMed Holdings, Inc.'s Principal Accounting Officer, Joshua Aiello, reported a routine disposition of 393 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Orchestra BioMed Holdings, Inc.'s Chief Financial Officer, Andrew Lawrence Taylor, reported a routine transaction involving the withholding of shares to cover tax obligations related to the vesting of restricted stock units.

Orchestra BioMed Holdings, Inc. CEO and Chairperson David P. Hochman reported a routine transaction involving the withholding of shares to cover tax obligations related to the vesting of restricted stock units.

Darren Sherman, President and COO of Orchestra BioMed Holdings, Inc., reported a routine disposition of 45,843 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting, with no market sales occurring.

RTW Investments, LP, a significant shareholder in Orchestra BioMed Holdings, Inc., increased its holdings through a recent purchase of common stock.

RTW Investments LP reports the acquisition of 50,000 shares of Orchestra BioMed Holdings, Inc. at $2.53 per share, increasing their indirect holdings.

Director David P. Hochman acquired shares and options in Orchestra BioMed Holdings, Inc. on April 4, 2025, according to a Form 4 filing.

Joshua Aiello, Principal Accounting Officer of Orchestra BioMed Holdings, acquires 48,000 stock options on April 4, 2025, according to a Form 4 filing.

Darren Sherman, President and COO of Orchestra BioMed Holdings, was granted 115,708 restricted stock units (RSUs) on April 4, 2025, vesting over three years.

Andrew Lawrence Taylor, CFO of Orchestra BioMed Holdings, Inc., was granted 84,000 restricted stock units on April 4, 2025, according to a Form 4 filing with the SEC.

Principal Accounting Officer Joshua Aiello reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

David P. Hochman, a director and officer of Orchestra BioMed Holdings, Inc., disposed of shares to cover tax withholding obligations related to vesting restricted stock units.

Director Chris Cleary of Orchestra BioMed Holdings receives restricted stock units and stock options.

Director Jason Aryeh exercised stock options to acquire 11,700 shares of Orchestra BioMed common stock.

Orchestra BioMed's CEO, David Hochman, purchased 4,000 shares of common stock at an average price of $4.66 on December 23, 2024.

Orchestra BioMed's Chief Financial Officer, Andrew Taylor, purchased 1,000 shares of common stock at a weighted average price of $4.83.

Orchestra BioMed's CEO, David Hochman, purchased 5,000 shares of common stock at an average price of $4.91 on December 18, 2024.

Orchestra BioMed's Chief Financial Officer, Andrew Taylor, sold 34,403 shares to cover tax obligations related to vesting restricted stock units.

Darren Sherman, President and COO of Orchestra BioMed Holdings, sold 31,815 shares to cover tax obligations related to vesting restricted stock units.

Orchestra BioMed Holdings CEO David Hochman reports purchasing additional shares of the company's common stock through direct and indirect holdings.

Darren Sherman, President and COO of Orchestra BioMed Holdings, sold shares of common stock on September 9th and 10th, 2024, to cover tax obligations associated with the vesting of restricted stock units.

Director Eric S. Fain of Orchestra BioMed Holdings, Inc. sold shares of common stock between September 6 and September 10, 2024, to cover tax obligations associated with the vesting of restricted stock units.